Today Lonza celebrates the completion of another strategic project in China with the opening of our new Microbial Control Formulations Plant in Nanjing. This new state-of-the-art facility strenghthens the leading position of Lonza in the Microbial Control market and adds important capacity and capabilities to our Microbial Control offering. Nanjing is located in China’s eastern Jiangsu province which is ideally suited to service a majority of our Microbial Control Customers.
The new plant is focused on the manufacturing of formulations but is capable of manufacturing quaternary compounds as well. The plant fully complies with the Chinese Ministry of Health regulations and is a US EPA registered site. The plant will manufacture registered formulations for the hygiene, water treatment and materials protection industries. The plant is supported by microbiology, application and analytical labs along with regulatory services which will enable the production of customized formulations as well as Lonza formulated products. Lonza has an expansive portfolio of over 1000 internationally registered formulations. This coupled with our extensive formulations expertise ensures Lonza is capable of providing customers with offerings that meet the needs of the Chinese market.
“We are happy to have completed this strategic expansion project for our Microbial Control business on time and on budget. With the new facility in Nanjing we have significantly expanded our capacity and advanced our position in this critical market.”, comments Jeanne Thoma, Head of Lonza Microbial Control. “The design of our facility allows us great flexibility to manufacture formulated products using a wide range of active ingredients to meet our customer’s requirements.”
Lonza’s Microbial Control business is a global provider of products and services to the Hygiene and Preservation, Materials Protection and Water Treatment industries. Lonza’s Microbial Control business is dedicated to help protect the health & welfare of humans, animals, plants, and products.
Lonza is one of the world's leading suppliers to the pharmaceutical, healthcare and life science industries. Its products and services span its customers’ needs from research to final product manufacture. Lonza is the global leader in the production and support of active pharmaceutical ingredients both chemically as well as biotechnologically. Biopharmaceuticals are one of the key growth drivers of the pharmaceutical and biotechnology industries. Lonza has strong capabilities in large and small molecules, peptides, amino acids and niche bioproducts which play an important role in the development of novel medicines and healthcare products. Lonza is a leader in cell-based research, endotoxin detection and cell therapy manufacturing. Lonza is also a leading provider of value chemical and biotech ingredients to the nutrition, hygiene, preservation, agro and personal care markets.
Lonza is headquartered in Basel, Switzerland and is listed on the SIX Swiss Exchange. In 2008, Lonza had sales of CHF 2.937 billion. Further information can be found at www.lonza.com.
For further Information
Lonza Group Ltd
Head Corporate Communications
Tel +41 61 316 8624
Fax +41 61 316 9624
Lonza Group Ltd
Tel +41 61 316 8798
Fax +41 61 316 9798
Lonza Group Ltd
Tel +41 61 316 8728
Fax +41 61 316 9728